Forum Agenda

July 23, 15:30–17:30

Cross-border Investment Session

Stay tuned

15:20-15:35 Cross-borderM&A of Pharmaceutical Assets:Structures, Trends and Challenges
Frank Zhou: Partner, JunHeLLP

 

15:35-15:50 Offshore Listings of Biotech Companies - Key Considerations 
Ke Geng: Ph.D., Managing Partner、Member of the Firm's Policy Committee

 

15:50-16:05 Global Life Sciences Transactions and the Outbound Expansion of Chinese Innovative Drugs
Daniel Mathews:EY Global Life Sciences Sector Partner

 

16:05-16:40 Roundtable: Cross-Border Investment and Industrial Transactions of Innovative Drugs
Winnie Wang (Moderator): Partner, Pacific Bridge NY Fund
Yongling Shi: Partner, MING BIOVENTURES
Quan Fu: Partner, TTM Capital
Yunlong Song: Founder、CEO,Shanghai Cloudthera Bioscience Ltd. 
Yingjie Wu: Executive Director, Search & Evaluate, Business Development, Oncology R&D, AstraZeneca
Yu Zeng: Founder, Teal Rise Capital

 

16:40-17:30 Insight Dialogue: AI-driven Paradigm for China Biotech Innovation Globalization 
Tony Zhang, Ph.D., MBA (Moderator): CEO & Co-founder, BridgeBio Global
Tom Du, Ph.D.: Founder & Chairman, Evergreen Therapeutics
Bin Xiao, Ph.D., M.D.: Co-Founder & Chief Scientific Officer, Uni-Pioneers BioMed (UP-Bio)
Stanley Lau: CEO & Founder, Tailai Biosciences
Peter Zhang, EMBA: ex-Head of Strategy and Commercial Excellence & Operations, Biogen China